This randomized clinical trial evaluates the effectiveness of augmented-dose combination nicotine replacement therapy (NRT) versus standard-dose NRT and no-NRT control for cessation of dual combustible cigarette (CC) and electronic cigarette (EC) use. Adults who currently engage in dual use and are motivated to quit both products will be assigned to one of three 12-week interventions: (1) no pharmacotherapy (behavioral support only), (2) standard-dose NRT (21 mg nicotine patch + 4 mg lozenges, 5-20/day), or (3) augmented-dose NRT (21 mg + 14 mg patches + 4 mg lozenges, 5-30/day). All groups receive evidence-based behavioral support through the EX Program. Primary outcomes include biochemically confirmed dual abstinence and CC-only abstinence at 12 and 24 weeks. A subset of participants will provide blood and saliva samples to assess DNA damage biomarkers associated with tobacco use and cessation.

开始日期2026-10-10

申办/合作机构

The Medical University of South Carolina

[+2]

NCT07099638

/ Not yet recruiting临床2期IIT

Randomized Factorial Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation

Although the prevalence of smoking has declined among U.S. adults, smoking remains the leading preventable cause of cancer incidence and mortality. Quitting smoking increases life expectancy, and quitting at an earlier age is associated with more years of life gained. Effective pharmacotherapies to aid cessation are available, and the combination of behavioral support with pharmacotherapy optimizes cessation outcomes. Varenicline is an effective, first-line smoking cessation treatment, and recent research has investigated combination pharmacotherapy to improve the modest quit rates observed with monotherapy. The findings of two meta-analyses have indicated that varenicline combined with the nicotine patch was more effective than varenicline alone for smoking cessation However, no published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.

开始日期2026-09-01

申办/合作机构

University of Oklahoma

[+3]

NCT06811038

/ Not yet recruiting临床3期

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

开始日期2026-08-15

申办/合作机构

Fred Hutchinson Cancer Research Center

[+1]

100 项与尼古丁相关的临床结果

登录后查看更多信息

100 项与尼古丁相关的转化医学

登录后查看更多信息

100 项与尼古丁相关的专利（医药）

登录后查看更多信息

34,344

项与尼古丁相关的文献（医药）

2026-12-01·Journal of Cardiovascular Translational Research

Towards Neoatherosclerosis: A Porcine Model for Enhanced Device Testing

Article

作者: Speck, Ulrich ; Haase, Tobias ; Hauptmann, Ralf ; Gemeinhardt, Ole ; Loechel, Melanie ; Schannor, Mathias ; Xie, Jing ; Bettink, Stephanie

Abstract:

The porcine in-stent stenosis model has been essential for developing drug-coated devices but does not replicate the hyperlipidemic, pro-atherogenic conditions driving neoatherosclerosis. We aimed to establish a practical porcine model for testing endovascular therapies targeting neoatherosclerosis. Juvenile pigs were fed a high-fat, nicotine-supplemented diet (HFDN). After two weeks, bare-metal stents were implanted in coronary and peripheral arteries; controls received a standard diet. Four weeks later, stented, and non-stented artery segments were analyzed. HFDN feeding induced elevated serum LDL and cotinine. At follow-up, in-stent late lumen loss was significantly greater in peripheral arteries (A. iliaca: 2.3 ± 0.6 vs. 1.1 ± 0.5 mm; A. femoralis: 3.4 ± 1.2 vs. 2.0 ± 0.4 mm), but not coronary arteries. HFDN-fed pigs showed distinct signs of early neoatherosclerosis, including peri-strut foam cell accumulations and atheroma formation. Elemental imaging and chemical analysis confirmed increased calcium phosphate deposition in arteries of HFDN-fed pigs. This straightforward protocol enables testing of devices aimed at preventing or treating neoatherosclerosis.

2026-12-01·Toxicology reports

Comparison of effects of charcoal versus electric heating of waterpipe tobacco on carbon monoxide levels; cardiovascular measures; benzene, pyrene, and nicotine uptake; and subjective reactions

Article

作者: Liles, Sandy ; Zaki, Flora K ; Kassem, Noura O ; Kassem, Nada O F

Toxicants are released from charcoal burned to heat waterpipe tobacco (WPT) and from WPT itself. This natural home setting trial tested a strategy to reduce harm of WPT use by comparing the effects of charcoal versus electric heating of WPT on outcome measures of toxicity. Fifty WPT smokers and 25 non-smokers (controls) participated. Within-subjects measures were collected in charcoal heated and in electric heated WPT smoking sessions. Pre-to-post differences in levels of ambient carbon monoxide (CO), exhaled CO, and heart rate were significantly lower when WPT was electrically heated; there were no differences for urinary biomarkers of nicotine, benzene and pyrene uptake. Comparing levels of controls to post smoking levels of urinary biomarkers of exposure to WPT indicated that electric heating of WPT versus charcoal heating did not significantly reduce exposure to the addictive drug nicotine or the toxicant pyrene, but did significantly reduce exposure to the carcinogenic compound benzene. Furthermore, we found visual evidence of charred WPT from electric sessions, suggesting excessively heated WPT. Participants reported smoking electric-heated WPT was less appealing; harsher and hurt their throat; but healthier and cleaner. To prevent negative subjective reactions from smokers and potential adverse health effects, electric heating devices should be regulated to prevent overheating and excessive thermal degradation of WPT. The findings also inform a harm reduction strategy, particularly for children living in homes of WPT smokers: smokers who use burning charcoal to heat WPT should avoid smoking indoors, as ambient CO levels proved significantly higher indoors than outdoors.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Effects of Nicotine administration on α7nAChR, miR-124, STAT3, and inflammatory markers in Rat Lung Tissue

Article

作者: Asaadi, Fatemeh ; Doustvandi, Mohammad Amin ; Hajiasgharzadeh, Khalil ; Alipour, Mohammad Reza ; Karimi-Sales, Elham ; Mansoori, Behzad ; Dastmalchi, Narges

BACKGROUND:

Nicotine, the major alkaloid in tobacco, interacts with nicotinic acetylcholine receptors (nAChRs), particularly α7nAChR, which is involved in inflammatory regulation. MicroRNA‑124 (miR‑124) and signal transducer and activator of transcription 3 (STAT3) also participate in inflammatory signaling. This study investigated the effects of nicotine on α7nAChR, miR‑124, phosphorylated STAT3 (p‑STAT3), MCP‑1, and IL‑10 expression in rat lung tissue.

METHODS:

Adult male Wistar rats (n = 8/group) received different doses of nicotine. Lung tissues were collected for molecular analyses. Expression of α7nAChR and miR‑124 was assessed using quantitative real‑time PCR (qRT‑PCR). Protein levels of α7nAChR and p‑STAT3 were evaluated by Western blotting, and MCP‑1 and IL‑10 levels were measured using ELISA.

RESULTS:

Nicotine exposure was associated with a dose‑dependent increase in α7nAChR expression. miR‑124 expression increased at the lower nicotine dose but decreased at higher doses. Alterations in p‑STAT3 protein levels were also observed following nicotine administration. MCP‑1 levels decreased at the lower dose and increased at higher doses, whereas IL‑10 levels increased in nicotine‑treated groups.

CONCLUSION:

Nicotine administration was associated with changes in α7nAChR, miR‑124, p‑STAT3, MCP‑1, and IL‑10 expression in rat lung tissue, suggesting a potential association between nicotine exposure and inflammatory signaling pathways in the lung.

1,130

项与尼古丁相关的新闻（医药）

2026-08-11

·北京铭道医疗

你身上的“烟味”，正在伤害最爱的TA！

前言大家对于“二手烟”比较熟知，但是否听过“三手烟”？听起来可能有些陌生，但它出现的位置却非常常见，如我们的家中、车内，甚至衣物上，成为威胁家人，尤其是儿童健康的“隐形杀手”！一篇近期发表在Clinical Science杂志的一篇实验研究发现：幼年短期接触三手烟（THS）会显著提升小鼠成年后肺腺癌发病风险，并完整阐明了三手烟促癌的分子细胞机制，首次提供三手烟直接诱发肿瘤的动物证据。 DOI: 10.1042/CS20171521 1 关于三手烟的危害三手烟，是指烟草烟雾中的有害物质，在烟雾散去后，吸附并残留在室内表面（如墙壁、地板、家具、窗帘、衣物，甚至灰尘中）的污染物。含有多种已知的致癌物，如多环芳烃（PAHs）和烟草特有亚硝胺（TSNAs）。更令人担忧的是，二手烟中的尼古丁沉降后，会与室内常见的亚硝酸（如燃气燃烧产生）反应，持续生成新的亚硝胺类致癌物。这意味着，即使不在室内吸烟，这些有害物质也可能在不断滋生。值得重视的是，相比于成年人，婴幼儿是三手烟的高危受害群体：小孩子更喜欢在地板、地毯上爬行、玩耍，经常用手触摸各种表面，并有“吃手”或把玩具放入口中的习惯，大大增加了通过皮肤接触和口部摄入三手烟污染物的机会，且他们的呼吸/皮肤/免疫系统发育尚不成熟，面对三手烟也更加脆弱。目前，已有体外细胞实验证实三手烟会诱发DNA损伤、代谢紊乱、脏器损伤。 2 研究结果：三手烟诱发肿瘤！虽然三手烟的危害多，但此前无动物活体证据证明三手烟会直接诱发肿瘤。基于此，该项研究人员使用对肺癌易感的A/J小鼠模型进行实验，让它们在4周-7周龄（相当于人类的幼儿期）期间，持续接触含有三手烟残留物的布料，模拟了儿童在家中接触三手烟的场景。接触时间仅为3周。实验结果极具警示性：在停止接触40周后（相当于小鼠的中年），幼儿期接触过三手烟的小鼠，其肺部肿瘤的发生率显著高于从未接触过的小鼠。图：三手烟暴露可增加A/J小鼠的肺癌发病率不仅如此，幼儿期接触三手烟的小鼠不仅更容易得肿瘤，其肿瘤的体积也更大，部分达到2mm；并且有部分小鼠出现了多个（超过3个）肺部肿瘤，而对照组中没有出现这种情况。病理分析确认这些肿瘤为肺腺癌——人类最常见的肺癌类型之一。这项研究首次提供了直接的实验证据，证明早期、短期的三手烟暴露，足以对未来的癌症发生风险产生长远影响。 3 保持健康方式保卫身体健康总之，上述研究的结论非常明确，除了避免在有人的室内吸烟外，我们更需要警惕那些残留的“烟味”。保持健康生活方式的重要性不言而喻。日本学者1992年在《Preventive Medicine》上发表了题为“Healthy lifestyles are associated with higher natural killer cell activity”的文章。该研究对62名30至60岁的健康男性进行了调查，通过问卷评估他们的八种健康习惯，如吸烟、饮酒、睡眠等，并分组比较。结果发现，具有良好生活习惯的个体，其NK细胞活性明显高于生活习惯较差的人。不同生活方式个体的NK细胞活性生活方式对免疫功能的影响如何，以上的这些研究都为我们提供了有力的证据。连续的熬夜加班，身体得不到充分休息；长期饮食不规律，摄入大量高糖、高盐、高脂肪食物，这些不健康的生活方式无时无刻都在影响着你的免疫健康，给自己的免疫系统带来了混乱和干扰，让它们难以正常工作。免疫细胞是免疫力的主要组成，免疫细胞的“健康”与否，是决定免疫力的关键因素。长此以往，带来的结果可能不仅是免疫力下降，更会增加患癌等严重疾病的风险。 4 定期检测细胞收获美好未来既然免疫细胞如此重要，想要守护免疫健康，除了坚持日常调养、践行健康生活方式外，更要清楚了解自身的免疫底数。通过科学的免疫检测，我们可以精准量化免疫细胞的活性与功能状态，及时发现潜在风险，让健康管理由“凭感觉”转变为“靠数据”。目前，依托于MICA+MISS免疫力全面检测及量化评估体系，您可以便捷地获取全面、精准的免疫健康评估报告。开展免疫检测，相当于为自己的身体安装了一套高灵敏度的“健康预警雷达”。无论是建立个人免疫基线，还是在亚健康状态下排查隐患，这份详尽的检测数据都能帮助医生制定更具针对性的干预策略，助您以更科学、更从容的姿态，筑牢抵御疾病的坚实防线。【注】文章内容旨在科普细胞知识，进行学术交流分享，了解行业前沿发展动态，不构成任何应用建议。参考文献向上滑动阅览 [1] Wael Awad,Jemma R. Mayall,Weijun Xu，et al. Cigarette smoke components modulate the MR1-MAIT axis, Journal of Experimental Medicine (2024). DOI:10.1084/jem.20240896 [2] Hang B, Wang Y, Huang Y, et al. Short-term early exposure to thirdhand cigarette smoke increases lung cancer incidence in mice. Clin Sci (Lond). 2018 Feb 28;132(4):475-488. [3] Thakur A, Zhang K, Chen J, et al. Pulmonary neuroendocrine cell-derived exosomes regulate iron homeostasis and oxidative stress in lung neurons. Sci Adv. 2026 Apr 10;12(15):eady2696. [4] Sarker N, Trisha NF, Hasan NT, et al. Association Between Tobacco Smoke Exposure and Cadmium Biomarkers in the US Population: NHANES 2015-2020. Biol Trace Elem Res. 2026 Apr [5] Brauning, A., Rae, M., Zhu, G., Fulton, E., Admasu, T. D., Stolzing, A., & Sharma, A. (2022). Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions. Cells, 11(6), 1017. [6] Immune thrombocytopenia associated with Mycoplasma pneumoniae infection: a case report and review of literature https://pubmed.ncbi.nlm.nih.gov/19474700/ [7] Association between physical exercise and mental health in1.2 million individuals in the USA between 2011 and 2015:a cross-sectional study Published:August 08,2018 DOI:https://doi.org/10.1016/S2215-0366(18)30227-X [8] Wang, X., Fu, S. Q., Yuan, X., Yu, F., Ji, Q., Tang, H. W., Li, R. K., Huang, S., Huang, P. Q., Qin, W. T., Zuo, H., Du, C., Yao, L. L., Li, H., Li, J., Li, D. X., Yang, Y., Xiao, S. Y., Tulamaiti, A., Wang, X. F., … Zhang, Z. G. (2024). A GAPDH serotonylation system couples CD8+ T cell glycolytic metabolism to antitumor immunity. Molecular cell [9] Fondell, E., Axelsson, J., Franck, K., Ploner, A., Lekander, M., Bälter, K., & Gaines, H. (2011). Short natural sleep is associated with higher T cell and lower NK cell activities. Brain, behavior, and immunity, 25(7), 1367–1375. [10]Kusaka, Y., Kondou, H., & Morimoto, K. (1992). Healthy lifestyles are associated with higher natural killer cell activity. Preventive medicine, 21(5), 602–615. 文章来源于网络，转载此文是出于传递更多信息之目的。若有来源标注错误或侵犯了您的合法权益，请作者持权属证明与本网联系, 我们将及时更正、删除，谢谢。

2026-08-10

·产品狗的猫窝

AI造病毒登Science、21亿美元融资创纪录、化学模型跑通但生物模型卡脖子——8月10日AI制药全线扫描

过去48小时，AI与生物医药的交叉领域密集释放重磅信号。斯坦福团队用生成式AI从零设计出16种自然界不存在的全新病毒，成果正式登上Science；谷歌旗下Isomorphic Labs完成21亿美元B轮融资，刷新AI制药单轮融资纪录；Recursion与罗氏的120亿美元合作迎来首个里程碑——AI地图锁定的首个神经科学靶点获实验验证。与此同时，国内行业论坛上，多位产业人士坦承AI化学模型已交出成绩单，但生物模型仍是横亘在"从靶点到临床"之间的死亡谷。以下逐一梳理近期最值得关注的动态。斯坦福AI从零设计16种全新病毒，成果登Science 据Science杂志正式发表的论文，美国斯坦福大学联合加州Arc研究所团队使用名为Evo 1和Evo 2的生成式AI模型，以天然噬菌体ΦX174为模板，让AI生成完整的病毒基因组。研究团队从AI产出的数千个候选基因组中筛选出302个进行实验室合成，最终获得16株具有完整生物活性的噬菌体，能够感染并杀灭大肠杆菌，且基因序列在自然界中并不存在。部分AI设计的噬菌体在杀灭大肠杆菌方面甚至优于天然噬菌体。研究负责人Brian Hie表示，这是首次证明生成式设计能够生成完整的功能性基因组。该成果2025年9月以预印本形式公开，2026年8月正式发表于Science，标志着AI在生物安全领域的能力边界正在快速扩张。Isomorphic Labs完成21亿美元B轮融资，AI药物进入临床加速期 Alphabet旗下AI药物发现公司Isomorphic Labs宣布完成21亿美元B轮融资，由Thrive Capital领投，Alphabet和主权基金跟投，创下AI制药领域单轮融资纪录。据多家媒体报道，这笔资金将用于推进AI发现的药物候选分子进入临床试验阶段。Isomorphic Labs由DeepMind联合创始人Demis Hassabis领导，2026年2月已推出一体化研发引擎IsoDDE，覆盖靶点发现、分子设计、结合活性预测全流程。公司目前与礼来、诺华、强生达成研发合作，潜在里程碑总额近30亿美元。Recursion与罗氏120亿美元合作迎里程碑：首个AI验证神经科学靶点据Noah News报道，Recursion、罗氏与基因泰克的合作伙伴关系取得关键进展——通过AI构建的神经科学靶点图谱中，首个靶点已获得实验验证，三方计划围绕该靶点共同开发早期小分子项目。这笔潜在总额高达120亿美元的合作，被认为是AI在生物制药领域价值兑现的重要标志，说明AI不仅能做建模，更能产出可操作的生物学洞见。GSK 1.1亿美元深化Relation Therapeutics合作，BMS部署Schrödinger AI共科学家据Pharmaceutical Executive等多家媒体报道，GSK与英国生物技术公司Relation Therapeutics达成价值最高1.1亿美元的深化合作协议，双方将生成大规模人类细胞数据集并构建AI模型以发现新药靶点，扩展此前聚焦纤维化疾病和骨关节炎的合作范围。同一周，百时美施贵宝宣布与Schrödinger签署软件协议，部署后者的Bunsen agentic共科学家平台，同时扩建42.7万平方英尺的圣迭戈研发中心并采购英伟达最新的Vera Rubin架构DGX SuperPOD超级计算集群。头部药企正从"试用AI"转向大规模基础设施投入。Greenstone Biosciences获NIH资助，AI驱动DMD心肌病药物发现据BioPharma BoardRoom报道，Greenstone Biosciences获得美国国立卫生研究院下属NHLBI颁发的Catalyze R61资助，用于推进杜氏肌营养不良症心肌病的AI驱动药物发现。该项目将结合iPSC生物样本库、蛋白质组学、计算药物筛选和生成式AI，发现针对心肌纤维化和扩张型心肌病的新型候选药物。DMD患者中约四分之一无法耐受或响应现有皮质类固醇治疗，目前没有针对心脏瘢痕的获批疗法。该项目启动正值FDA将ISTAND新方法论项目永久化、FDA现代化法案3.0通过众议院审议之际，监管对人类相关模型的支持力度空前。Dassault Systèmes 18亿美元收购ArisGlobal，Tempus 15亿美元收购Personalis 据ITBusinessToday报道，法国工业软件巨头达索系统宣布以约18亿美元收购ArisGlobal，后者服务全球超200家组织，包括约半数全球前50大生物制药公司，年处理超1200万份患者安全报告。此次收购旨在将ArisGlobal的法规合规与临床数据平台与达索的药物发现、临床开发和制造能力整合，打造AI驱动的生命科学智能平台。与此同时，据BioSpace报道，AI精准医疗公司Tempus AI宣布以15亿美元收购Personalis，将其分子残留病灶检测技术整合进AI精准肿瘤学平台。Personalis的NeXT Personal MRD检测已在三个适应症获得Medicare覆盖，Q2初步收入2240万美元，检测量同比增长33%。Twist Bioscience融资3亿美元加注AI合成生物学据BriefGlance报道，合成生物学龙头Twist Bioscience宣布将公开募股规模从2.5亿美元上调至3亿美元，以每股96美元定价发行312.5万股。高盛和William Blair担任承销商。公司Q3收入创纪录达1.184亿美元，同比增长23.2%，已连续14个季度实现环比增长。合成生物学赛道预计从2025年的189亿美元增长至2033年的690亿美元，Twist此次融资将重点投入AI驱动的药物发现和制造扩张。英矽智能Rentosertib启动III期临床，BD合作总额超70亿美元据雪球及BioPharma APAC报道，港股AI制药第一股英矽智能核心管线Rentosertib已于2026年7月正式启动III期临床试验，用于特发性肺纤维化治疗，计划在全国47个中心入组320例受试者。这是全球首个由AI全流程设计的药物进入III期注册性研究，从靶点发现到候选分子确认仅耗时约18个月。现有IPF药物尼达尼布年销售额超40亿美元。2026年上半年公司实现里程碑式扭亏，年内新签BD合作潜在总额接近70亿美元，合作方覆盖礼来、SK生物制药、武田、康哲药业等。行业深度：化学模型跑出成绩单，生物模型仍卡"死亡谷" 据科创板日报报道，在2026BPD第九届生物药工艺发展大会上，多位产业人士对AI制药的真实能力边界进行了冷静审视。镁伽科技联合创始人张琰介绍，其鲲鹏实验室仅用4个月完成18个靶点56轮干湿实验闭环，工作量相当于传统模式下四五十名科研人员三四年的产出。剂泰科技联合创始人王文首表示，AI已将药物早期开发周期从三四年压缩至最多一两年。然而，启明创投副总裁黄硕和百英生物高级副总裁史雷均指出，AI在靶点发现和临床转化阶段仍是瓶颈，从靶点到人体的"死亡之谷"尚未跨越。摩根士丹利在最新研报中预测，化学模型是药企研发体系的"加速器"，但生物模型的发展水平才决定AI制药行业的价值上限。趋势信号第一个信号：科技巨头从"模型输出"转向"全栈投入"。Isomorphic Labs 21亿美元融资、BMS采购英伟达最新超级计算集群、达索18亿美元收购ArisGlobal，头部玩家正在把AI从辅助工具升级为研发基础设施的核心层。第二个信号：AI制药的价值验证从"讲故事"进入"订单兑现"。英矽智能Rentosertib III期启动、Recursion与罗氏合作产出首个实验验证靶点、Twist Bioscience 3亿美元融资获得市场超额认购，资本和临床数据正在共同推动行业从概念期迈入收获期。第三个信号：生物模型成为下一轮竞争的关键变量。多位业内人士指出化学模型已趋成熟，但生物学复杂性和临床转化的不确定性仍是最大瓶颈，谁能在生物模型上取得突破，谁就掌握AI制药2.0时代的定价权。重点关注方向近期建议密切关注以下方向：AI驱动药物的III期临床数据读出进度，尤其是英矽智能Rentosertib和Nxera NBI-1117568的注册性研究结果；大型药企的AI基础设施采购和并购动向，特别是围绕临床数据平台和生物模型的整合交易；FDA对AI药物研发工具和新方法论的监管态度演变，以及FDA现代化法案3.0的参议院最终投票结果。

2026-08-10

·药物分子设计

代谢工程与合成生物学｜佐治亚大学李晨翊课题组招收全奖博士、博士后

PI Introduction Dr. Chenyi Li will join the University of Georgia in October 2026 as a tenure-track Assistant Professor, directing the Li Lab for Metabolic Engineering (LiME Lab) through a joint appointment between the School of Chemical, Materials, and Biomedical Engineering in the College of Engineering (51%) and the Department of Physiology and Pharmacology alongside the Isakson Center for Neurological Disease Research (ICNDR) in the College of Veterinary Medicine (49%). The LiME Lab operates at the frontier of applied synthetic biology and translational metabolic engineering, bridging upstream innovations in genetic biosensors and metabolic pathway engineering with downstream applications in translational neurotherapeutics for neurodegenerative disorders like Parkinson’s and Alzheimer’s, as well as sustainable biomanufacturing for a circular bioeconomy. Dr. Li earned his B.S. in Biological Engineering from the Beijing Institute of Technology (2013-2017) under Prof. Chun Li and his Ph.D. from the UGA College of Engineering (2017-2022) under Prof. Yajun Yan. He subsequently completed his postdoctoral training at the University of California, Berkeley and the Joint BioEnergy Institute (2022-2026) under the mentorship of Prof. Jay D. Keasling, a pioneer in synthetic biology and member of the National Academy of Engineering. His research has appeared in leading peer-reviewed journals, including Nature Catalysis, PNAS, Metabolic Engineering, Green Chemistry, and Trends in Biotechnology. In October 2026, Dr. Li will join UGA to build an interdisciplinary research team dedicated to reprogramming living microbial systems for human health and environmental sustainability. Introduction for the University and Department. The University of Georgia (UGA) is the first chartered public university in the United States and holds the distinction of being a “Public Ivy”, consistently ranking among the top 20 public universities and top 50 national universities according to U.S. News & World Report. Located in Athens GA, frequently recognized as one of the nation’s premier college towns, UGA ranks No. 2 nationwide for “Best Student Life” (Niche). The LiME Lab operates at the intersection of dynamic engineering and biomedical innovation through a joint appointment bridging the College of Engineering and the Department of Physiology and Pharmacology within the College of Veterinary Medicine. Home to the Isakson Center for Neurological Disease Research (ICNDR), the department consistently ranks among the top 10 nationally in research funding and scientific impact. By leveraging the College of Engineering’s cutting-edge infrastructure alongside ICNDR’s premier research facilities, the LiME Lab provides team members with world-class resources, an intensely collaborative environment, and exceptional opportunities for professional growth. Research Directions The LiME Lab operates at the intersection of metabolic engineering, applied synthetic biology, and translational neurotherapeutics. Our research program centers on four interconnected pillars: Microbial Cell Factories & Next-Generation Therapeutics: Developing high-efficiency microbial platforms, with an emphasis on probiotic hosts and non-conventional microorganisms, for the biosynthesis of high-value small molecules, pharmaceutical precursors, and neuroactive compounds. Genetically-Encoded Biosensors & Dynamic Pathway Control: Designing novel genetic biosensors and metabolic regulation strategies to achieve precise, real-time control over complex biosynthetic pathways and conditionally triggered therapeutic delivery. Translational Neurotherapeutics & Smart Live Biotherapeutics: Translating synthetic biology tools into targeted neurological interventions, including living biotherapeutic systems capable of site-specific drug/neurotransmitter delivery and engineered safety mechanisms (e.g., robust genetic "kill switches"). Sustainable Biomanufacturing & Circular Bioeconomy: Engineering non-conventional microbial hosts to upcycle low-cost agricultural side streams and waste feedstocks into high-value biochemicals and functional molecules. Open positions 1. Ph.D. Students Number: 2-3 (Fall 2027, full assistantship support with tuition waiver and monthly stipend) Qualifications & Requirements: o A Master’s degree in Biological Engineering, Chemical Engineering, Biomedical Engineering, Chemistry, Biochemistry, Microbiology, or a closely related field. Exceptional candidates with a Bachelor’s degree and strong research experience will also be fully considered. o A demonstrated passion for metabolic engineering, synthetic biology, biosensor design, or live biotherapeutics engineering; o Prior hands-on research experience in molecular biology, gene editing (e.g., CRISPR), microbial engineering, or fermentation technology. o Excellent English communication, and solid fundamental academic writing abilities. o International students must meet the UGA Graduate School’s English language proficiency requirements (TOEFL ≥ 80 or IELTS ≥ 6.5). No GRE score is required. 2. Postdoctoral Researcher Number: 1 (Target start date in Nov 2026 to Jan 2027) Qualifications & Requirements: o Ph.D. in Biological Engineering, Chemical Engineering, Biomedical Engineering, Chemistry, Biochemistry, Microbiology, or a closely related field (completed or near completion before the start date). o A strong background and hands-on expertise in metabolic engineering, synthetic biology, genetic biosensor development, or microbial genetic manipulation. o A proven track record of scientific productivity, evidenced by first-author/co-first author publications in peer-reviewed, high-impact journals. o Ability to drive research projects independently, troubleshoot complex experimental workflows, and thrive in a highly collaborative team environment. o Motivation to assist in mentoring graduate and undergraduate students, contribute to grant proposal writing, and help manage lab operations. How to Apply Please submit your application materials via email to chenyiliucb@berkeley.edu. Please use the subject line format when sending the required materials: “Position Applied For - Your Full Name”. PhD Students: Please send you most current Curriculum Vitae (CV), a brief statement of past research experience (1-page), a cover letter (1-page), and contact information for two references; formal applications must be submitted online through the UGA Graduate School Online Application Portal. Postdoctoral Researchers: Please send you most current Curriculum Vitae (CV), a statement of research experience and future research interests (2-page), PDFs of representative papers (preprints or manuscripts currently under review/revision are encouraged to be included), and contact information for two references. Applications will be reviewed on a rolling basis until the positions are filled. Early submission is encouraged. -END-

基因疗法临床研究

100 项与尼古丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03365	尼古丁	N07BA01	DB00184

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尼古丁成瘾	韩国	SAEHAN PHARM	2007-08-28
烟草依赖	澳大利亚	Johnson & Johnson Pacific Pty Ltd.	2001-11-27
尼古丁依赖	美国	Haleon US Capital LLC	1984-01-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肢端雀斑恶性黑色素瘤	临床3期	美国	McNeil AB	2011-03-01
药物性运动障碍	临床2期	美国	Neuraltus Pharmaceuticals, Inc.	2009-10-01
帕金森病	临床2期	美国	Neuraltus Pharmaceuticals, Inc.	2009-10-01
肺癌	临床1期	美国	Pfizer Inc.	2017-06-16
衰老	临床前	中国	深圳先进技术研究院	2023-02-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00962988 (CTgov)	临床4期	脑卒中 \| 短暂性脑缺血发作 \| 尼古丁成瘾 ... 更多	194	Cost-Free Pharmacotherapy Group (Cost-Free Group)	壓齋觸壓選衊衊繭遞夢 = 積鏇衊餘壓築鏇衊製繭鹹憲範襯膚網艱顧構醖 (夢廠選鹽鏇製積糧壓選, 範夢鑰願鬱膚構膚構餘 ~ 網遞鹹淵簾願積淵醖鑰) 更多	-	2026-08-10
				Prescription Only Group (Prescription Only Group)	壓齋觸壓選衊衊繭遞夢 = 襯糧齋構積憲鹽餘網繭鹹憲範襯膚網艱顧構醖 (夢廠選鹽鏇製積糧壓選, 蓋齋艱襯願網餘網醖顧 ~ 衊積窪遞繭製蓋鑰鑰築) 更多
NCT05004662 (CTgov)	N/A	尼古丁成瘾	502	Counseling+Nicotine patch (Standard Treatment)	廠選憲壓壓鹽淵鏇夢製 = 願網積窪網鹽範艱襯選繭壓襯衊鹹齋艱網遞齋 (齋廠願鏇鏇築鹽蓋遞齋, 簾淵壓鏇衊鹹鹽鹹餘膚 ~ 齋憲壓鬱構選齋衊構齋) 更多	-	2026-08-04
				Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment)	廠選憲壓壓鹽淵鏇夢製 = 鹽築窪願構遞製憲糧觸繭壓襯衊鹹齋艱網遞齋 (齋廠願鏇鏇築鹽蓋遞齋, 積餘顧觸鹹網獵窪鹽鑰 ~ 窪觸膚鏇願築壓壓憲獵) 更多
NCT05130788 (CTgov)	N/A	尼古丁成瘾	150	Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2))	鏇衊積蓋範襯廠選憲鑰 = 襯夢憲獵廠窪糧襯範鏇選願淵廠糧築鏇獵衊鹹 (窪獵製鑰窪艱膚壓醖鏇, 糧鹹衊糧積製願壓鏇齋 ~ 鬱壓選製蓋觸糧鏇鬱製) 更多	-	2026-07-31
				Nicotine Replacement Therapy (NRT) (Control Group (Aim 2))	選願簾鏇鏇鑰繭鹹觸膚 = 積醖製製餘鑰窪顧夢遞襯餘鏇艱壓繭憲壓鹹壓 (膚繭壓鏇廠積觸積範網, 繭網醖願製衊簾觸餘觸 ~ 糧鹽築蓋願積鹽鬱顧壓) 更多
NCT03691350 (CTgov)	早期临床1期	-	66	Bronchoscopy with Bronchoalveolar Lavage (Group I (Usual Cigarette Brand))	願憲夢遞鹹廠蓋範觸餘(構鏇醖蓋鑰糧壓觸網築) = 窪鑰醖膚顧鹹鏇糧鬱齋襯簾顧膚願繭鏇鏇艱獵 (構艱鏇願築顧鹽觸襯築, 0.3059) 更多	-	2026-04-23
				Electronic Cigarette (Group II (SREC With Nicotine))	願憲夢遞鹹廠蓋範觸餘(構鏇醖蓋鑰糧壓觸網築) = 鹽淵製願製網壓糧築齋襯簾顧膚願繭鏇鏇艱獵 (構艱鏇願築顧鹽觸襯築, 0.2939) 更多
NCT06051474 (CTgov)	临床4期	尼古丁成瘾 \| 吸烟 \| 尼古丁依赖	23	Nicotine Replacement Product	窪襯構鏇醖製築選獵衊 = 鹹鬱觸網構積鑰廠簾壓窪窪構遞蓋廠範築鑰遞 (襯鏇選壓齋醖淵願餘獵, 蓋窪網積衊淵鏇獵廠積 ~ 網糧遞衊夢壓簾顧築遞) 更多	-	2026-04-16
NCT03652740 (CTgov)	临床1期	-	25	Placebo+Nicotine+Methylphenidate (Caffeine Chooser)	糧醖壓廠構襯鑰淵憲網(鏇醖壓鏇鏇齋蓋積鹽壓) = 範夢蓋蓋簾鏇願廠憲鏇鏇蓋觸壓糧積範鹽衊繭 (網願鬱襯艱積廠簾選遞, 1.20) 更多	-	2026-02-02
				Placebo+Nicotine+Methylphenidate (Caffeine Non-Chooser)	糧醖壓廠構襯鑰淵憲網(鏇醖壓鏇鏇齋蓋積鹽壓) = 遞築積壓範積製繭糧齋鏇蓋觸壓糧積範鹽衊繭 (網願鬱襯艱積廠簾選遞, 0.60) 更多
NCT04965181 (CTgov)	N/A	吸烟	504	Mindfulness-Based Addiction Treatment+Nicotine Replacement Therapy (Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully)	壓築襯廠鹽夢憲憲醖膚 = 衊願製廠壓衊願膚廠憲壓廠窪餘願範積鬱製鏇 (繭繭觸膚膚窪淵窪獵淵, 憲觸獵鏇膚願網廠製觸 ~ 構壓齋獵廠憲簾構淵壓) 更多	-	2025-12-30
				Self-help materials+Nicotine Replacement Therapy (iQuit Mindfully)	壓築襯廠鹽夢憲憲醖膚 = 獵蓋範膚齋窪觸網網鹽壓廠窪餘願範積鬱製鏇 (繭繭觸膚膚窪淵窪獵淵, 構廠願廠夢壓積網鑰夢 ~ 壓糧構夢觸簾齋選淵襯) 更多
NCT06289192 (CTgov)	临床4期	肺癌 \| 烟草依赖	5	Lung Cancer Screening+Nicotine Replacement Product	憲膚鏇願製鹽齋顧鑰顧 = 襯積艱獵廠壓鬱蓋願蓋壓製鹽蓋選積襯襯衊襯 (繭願繭淵蓋憲餘鹹夢鏇, 糧顧鑰鬱壓膚積鹹鬱觸 ~ 衊齋憲鹽鑰選顧鹹鏇鏇) 更多	-	2025-09-10
NCT04038255 (CTgov)	临床4期	肿瘤	20	Self-help smoking cessation materials+Nicoderm (Usual Care)	觸艱簾鹽顧齋艱範壓鏇 = 衊醖膚衊築夢製鹽窪壓壓網繭構獵醖觸選選築 (膚觸觸構鹽艱淵膚顧鬱, 廠醖選鏇鹽襯淵壓網鬱 ~ 鬱廠顧壓鬱選網齋網淵) 更多	-	2025-09-09
				Craving-to-Quit app+Nicoderm (Craving-to-Quit App)	觸艱簾鹽顧齋艱範壓鏇 = 選鹽鬱製壓憲艱繭齋壓壓網繭構獵醖觸選選築 (膚觸觸構鹽艱淵膚顧鬱, 範獵遞製艱艱膚網鑰齋 ~ 選餘製膚遞鑰鹽憲齋襯) 更多
NCT04590404 (CTgov)	临床3期	吸烟	606	Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline	製築憲窪鏇鏇顧襯製齋 = 襯鑰鹽齋積醖鬱積襯齋餘鏇廠獵淵製鹽選廠獵 (壓壓窪蓋艱憲廠憲築構, 繭構鏇壓衊積鬱構鬱艱 ~ 醖顧鹹廠築鹽膚鹽選鬱) 更多	-	2025-06-05